138 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Thursday’s Close
NBIX Neurocrine Biosciences, Inc. $117.38 $10.62B Buy
Article Searches
4 Defensive Stocks to Buy Amid Shutdown and Brexit http://www.zacks.com/stock/news/347600/4-defensive-stocks-to-buy-amid-shutdown-and-brexit?cid=CS-ZC-FT-347600 Jan 16, 2019 - Defensive equities could ride out market unpredictability.
Neurocrine Suffers Setback In Tourette Study, But Still Has A Solid Pipeline https://seekingalpha.com/article/4230262-neurocrine-suffers-setback-tourette-study-still-solid-pipeline?source=feed_sector_healthcare Dec 26, 2018 - Neurocrine Biosciences announced that its phase 2b study using Ingrezza to treat patients with Tourette Syndrome failed to meet the primary endpoint.Ingrezza has already been approved by the FDA to tr
Shares Of Neurocrine Are Likely To Print $100 Again https://seekingalpha.com/article/4229342-shares-neurocrine-likely-print-100?source=feed_sector_healthcare Dec 20, 2018 - I'm initiating a long-term core position in Neurocrine Biosciences following a ~20% shave post Tourette syndrome failure and a ~40% shave from 52-week highs.Wholly-owned Ingrezza, for the treatment of
Neurocrine Hit Hard As T-Force GOLD Turns To Lead https://seekingalpha.com/article/4228063-neurocrine-hit-hard-t-force-gold-turns-lead?source=feed_sector_healthcare Dec 13, 2018 - Neurocrine announced that its T-Force GOLD study of Ingrezza in pediatric Tourette's had failed.The failure isn't a complete surprise, but removes Neurocrine's last late-stage pipeline asset from cons
Why Under Armour, Neurocrine Biosciences, and XPO Logistics Slumped Today https://www.fool.com/investing/2018/12/12/why-under-armour-neurocrine-biosciences-and-xpo-lo.aspx?source=iedfolrf0000001 Dec 12, 2018 - Find out which of these companies warned about its future results.
Neurocrine Biosciences' (NBIX) CEO Kevin Gorman on Q3 2018 Results - Earnings Call Transcript https://seekingalpha.com/article/4218511-neurocrine-biosciences-nbix-ceo-kevin-gorman-q3-2018-results-earnings-call-transcript?source=feed_sector_healthcare Nov 05, 2018 - Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q3 2018 Results Earnings Conference Call November 5, 2018, 04:30 PM ET Executives Jane Sorensen - Executive Assistant Kevin Gorman - Chief Executive Officer
Neurocrine Biosciences, Inc. 2018 Q3 - Results - Earnings Call Slides https://seekingalpha.com/article/4218450-neurocrine-biosciences-inc-2018-q3-results-earnings-call-slides?source=feed_sector_healthcare Nov 05, 2018 - The following slide deck was published by Neurocrine Biosciences, Inc. in conjunction with their 2018 Q3 earnings call.
After hours: ELF leads gainers, losers include NBIX and THC https://seekingalpha.com/news/3405529-hours-elf-leads-gainers-losers-include-nbix-thc?source=feed_news_all Nov 05, 2018 - Top Gainers: ELF +18.5%. CVGI +12.8%. FN +11.3%. ATUS +8.8%. LASR +5.7%. Top Losers: FTDR -8.9%. NEOS -7.8% NBIX -6.2%. IIN -6.2%. THC -5.2%.
Drug Stocks to Post Earnings on Nov 5: MYL, NBIX, RARE, TARO http://www.zacks.com/stock/news/334797/drug-stocks-to-post-earnings-on-nov-5-myl-nbix-rare-taro?cid=CS-ZC-FT-334797 Nov 02, 2018 - We see how things are shaping up for the four pharma/biotech companies, which are scheduled to release second-quarter earnings on Nov 5.
Neurocrine Biosciences (NBIX) Q3 Earnings Preview: What to Look Out For http://www.zacks.com/stock/news/332335/neurocrine-biosciences-nbix-q3-earnings-preview-what-to-look-out-for?cid=CS-ZC-FT-332335 Oct 29, 2018 - Neurocrine (NBIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Pages: 123456...14

Page 1>

Related Companies

Name Exchange Price Mkt Cap
SGEN Seattle Genetics, Inc. NASDAQ $76.15 $12.09B
QGEN Qiagen N.V. NYSE $37.42 $8.5B
QGEN Qiagen N.V. NASDAQ $37.42 $8.5B
BLUE bluebird bio, Inc. NASDAQ $137.25 $7.43B
TECH Bio-Techne Corp NASDAQ $196.8 $7.43B
Sector: Health Care > Industry: Biotechnology: Biological Products (No Diagnostic Substances)
DeepLinks for Neurocrine Biosciences
NBIX - Google Finance https://www.google.com/finance?q=NBIX Industry related info and international coverage Summary News
NBIX - Bloomberg http://www.bloomberg.com/research/stocks/snapshot/snapshot.asp?ticker=NBIX Original news and commentary from Bloomberg Charts Financials with pensions Snapshot Earnings Transactions People Options